Journal of Vascular Surgery最新文献

{"title":"Hospital setting of endovascular repair influences procedural outcomes in blunt traumatic aortic injury.","authors":"John H Cabot, Micaella Zubkov, Lisa M Knowlton, Anna Romagnoli, David S Kauvar","doi":"10.1016/j.jvs.2025.04.021","DOIUrl":"https://doi.org/10.1016/j.jvs.2025.04.021","url":null,"abstract":"<p><strong>Background: </strong>Thoracic endovascular aortic repair (TEVAR) has become the mainstay of treatment for blunt thoracic aortic injuries (BTAI) over open repair. Since the arrival of TEVAR, hybrid operating rooms have emerged as highly specialized environments equipped to streamline endovascular and open cases. Procedure characteristics and outcomes may vary when TEVAR is performed in the setting of a standard operating room with a portable C-Arm vs in a hybrid operating room or interventional radiology (IR) suite with a fixed imaging system. The purpose of this study was to compare clinical characteristics and outcomes of TEVAR for BTAI across these settings. We hypothesize that cases performed with a C-Arm would lead to higher rates of complications.</p><p><strong>Methods: </strong>The PROOVIT registry (PROspective Observational Vascular Injury Treatment) captures trauma-specific outcomes related to vascular injury across 14 trauma centers in the United States. The registry was queried for BTAI undergoing TEVAR from 2012 to 2021. Cases were categorized as having been performed in a standard operating room with portable C-Arm imaging (C-Arm), or in a fixed imaging suite (hybrid room [Hybrid] or IR). Procedural characteristics and complications (arterial access, reintervention, stroke) were collected and compared using univariate analyses.</p><p><strong>Results: </strong>PROOVIT contained 199 TEVAR for BTAI: 82 C-Arm, 75 Hybrid, and 42 IR cases. There was no clear temporal trend in the setting TEVAR was performed. Demographics and mechanism of injury were similar between groups; Hybrid room procedures had higher median Injury Severity Score (ISS) (38; interquartile range [IQR], 14) than C-Arm (33; IQR, 15) and IR (29; IQR, 25; P = .02) and a higher proportion of cases with an Abbreviated Injury Scale head score of >3 (44% vs 28% C-Arm vs 24% IR; P = .06). Hybrid cases were most often delayed >6 hours from arrival (78% vs 48% vs 41%; P < .001), but C-Arm cases most frequently lasted >3 hours (34% vs 12% Hybrid vs 15% IR; P = .002). Use of C-Arm (P = .03) and time to TEVAR of <6 hours (P = .04) were predictors of complications. All strokes (n = 3) occurred in C-Arm cases (P = .04).</p><p><strong>Conclusions: </strong>Despite technological advances, TEVAR for BTAI is still performed frequently in a standard operating room with C-Arm imaging, rather than with a fixed imaging system in a hybrid operating room or IR suite. C-Arm procedures take longer and have higher complication rates, including stroke. TEVAR for BTAI is conducted most safely using a fixed imaging system in a hybrid operating room setting.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiproliferative endovascular drug technology is associated with fewer major reinterventions after femoropopliteal interventions for chronic limb-threatening ischemia.","authors":"Jeffrey J Siracuse, John A Kaufman, Alik Farber, Matthew T Menard, Kenneth Rosenfield, Michael S Conte, Andes Schanzer, Richard J Powell, Maarit Venermo, Gheorghe Doros, Peter Faries, Michael B Strong, Michael D Dake","doi":"10.1016/j.jvs.2025.04.029","DOIUrl":"https://doi.org/10.1016/j.jvs.2025.04.029","url":null,"abstract":"<p><strong>Objective: </strong>Conflicting data exist regarding the benefits of paclitaxel-based endovascular interventions (ENDO-Drug) for patients with chronic limb-threatening ischemia (CLTI). This analysis aims to evaluate the effect of such therapy in the Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial.</p><p><strong>Methods: </strong>The as treated dataset from the BEST-CLI Trial, a prospective randomized trial comparing surgical and endovascular revascularization for infrainguinal CLTI, was used to assess the association of ENDO-Drug (drug-coated balloons or drug-eluting stents) use and 3-year outcomes after initial technical success in the femoropopliteal (FP) segment. ENDO-Drug was compared with ENDO-No Drug interventions. Outcomes evaluated included major reinterventions (new bypass, interposition graft, thrombectomy, or thrombolysis), any reintervention, major adverse limb events/death, above-ankle amputations, and death.</p><p><strong>Results: </strong>There were 341 isolated FP endovascular procedures (186 ENDO-Drug, 155 ENDO-No Drug) performed in 341 patients; the majority were for tissue loss (66.3%). On Kaplan-Meier unadjusted analysis, ENDO-Drug was associated with fewer major reinterventions (16.7% vs 29.7%; P = .026), but similar any reinterventions (43.3% vs 55.6%; P = .16), major adverse limb events/death (42.4% vs 53.2%; P = .12), above-ankle amputation (14.1% vs 11.4%; P = .52), and death (21.5% vs 25%; P = .77). On risk-adjusted analysis, ENDO-Drug was associated with fewer major reinterventions (hazard ratio, 0.53; 95% confidence interval, 0.31-0.91; P = .02) and lower death (hazard ratio, 0.52; 95% confidence interval, 0.3-0.91; P = .02). Results were similar when excluding failures within 30 days. When considering any concomitant infrapopliteal interventions, there were 668 FP with or without any infrapopliteal endovascular interventions (377 ENDO-Drug, 291 ENDO-No Drug) performed. On risk-adjusted analysis, after excluding those patients who experienced revascularization failure within 30 days of the index procedure, there were no differences in outcomes overall.</p><p><strong>Conclusions: </strong>In patients with CLTI and isolated FP disease treated using endovascular therapy, ENDO-Drug was associated with lower 3-year major reinterventions and death. Endovascular interventions using paclitaxel-based drug technology should be considered in patients with CLTI and FP occlusive disease.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in supply, demand, and workforce adequacy in vascular surgery: Forecasting a national shortage.","authors":"Jason Silvestre, Mathew D Wooster, Sydney Seeger, Vincent L Rowe, Charles A Reitman","doi":"10.1016/j.jvs.2025.04.071","DOIUrl":"10.1016/j.jvs.2025.04.071","url":null,"abstract":"<p><strong>Objective: </strong>There is currently a lack of research assessing the adequacy of the vascular surgery workforce in the United States (U.S.). The objective of this study was to determine the supply, demand, and adequacy of the vascular surgery workforce.</p><p><strong>Methods: </strong>This was a cross-sectional study of full-time equivalent (FTE) physicians in the vascular surgery workforce using data from the Health Workforce Simulation Model (2024 to 2037). Supply was defined as the number of FTEs within the vascular surgery workforce. Demand was defined as the number of FTE vascular surgeons needed to support U.S. health care needs. Workforce adequacy was defined as the ratio of supply over demand. Linear regression was used to analyze workforce trends over the study period. Ten additional surgical specialties were available for comparison of workforce adequacy.</p><p><strong>Results: </strong>From 2024 to 2037, the supply of the vascular surgeons remained constant at 5790, whereas the demand for vascular surgeons increased from 7860 to 9000 (14.5% increase; P < .001). This resulted in a decreasing vascular surgery workforce adequacy over the study period (73.7% to 64.3%; P < .001). Workforce adequacy was lowest in non-metropolitan areas compared with metropolitan areas (P < .001). In 2024, the states with the lowest workforce adequacy were Nevada (28.6%), Arkansas (33.3%), Delaware (33.3%), South Dakota (33.3%), and Mississippi (33.3%). In 2037, the states with the lowest workforce adequacy were Idaho (20.0%), Arkansas (22.2%), Hawaii (25.0%), and Nevada (25.0%). Vascular surgery ranked last among all surgical specialties for workforce adequacy in 2024 and 2037.</p><p><strong>Conclusions: </strong>Workforce adequacy in vascular surgery is projected to decrease significantly by 2037, with significant shortages expected in certain states and non-metropolitan areas. Vascular surgery ranked last in workforce adequacy across all studied surgical specialties. Future work is needed to develop strategies that increase the supply of vascular surgeons in the U.S. and ultimately improve workforce adequacy in vascular surgery.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-center comparative study of MANTA and ProGlide vascular closure devices in percutaneous endovascular aneurysm repair.","authors":"Rens Jorn Oosterveld, Chrissy van Wely, Pieter Bartholomeus Salemans, Ruben Nouwens, Lee Hans Bouwman, Ozan Yazar","doi":"10.1016/j.jvs.2025.05.040","DOIUrl":"10.1016/j.jvs.2025.05.040","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to compare the clinical outcomes of the MANTA and ProGlide devices in a real-world population of patients undergoing elective percutaneous endovascular aneurysm repair (pEVAR).</p><p><strong>Methods: </strong>All consecutive patients undergoing percutaneous EVAR (pEVAR) in a single center were retrospectively reviewed. Technical success was defined as achieving hemostasis after device deployment. Complications were registered, including improper sealing after deployment, to conform with the instructions for use, bleeding after leaving the operating room, occlusion, stenosis, and false aneurysm. The conversion rate to femoral cut-down was registered as well.</p><p><strong>Results: </strong>A total of 263 patients were included in the analysis, resulting in 511 common femoral artery puncture sites. There were 325 that were closed using MANTA and 186 using ProGlide. Technical failure occurred in 27 cases (8.3%) in the MANTA group and 29 cases (15.6%) in the ProGlide group (P < .001). Within these cases, improper sealing at the end of the procedure was found in 19 cases (5.8%) in the MANTA group and 26 (13.9%) in the ProGlide group (P = .002). Bleeding after the procedure ended occurred in two cases (1.2%) in the MANTA group and three cases (1.6%) in the ProGlide group (P = .721). Femoral cut-down was necessary in 15 cases in the MANTA group (4.6%). Cut-down was performed in 9 patients in the ProGlide group, representing 4.8% of the ProGlide group (P = .909).</p><p><strong>Conclusions: </strong>Both MANTA and ProGlide are safe options for the closure of large-bore arteriotomies in pEVAR. Although the ProGlide has a lower first success rate, its shortcomings are solved easily by adding another device, resulting in comparable conversion rates. Furthermore, ProGlide was less expensive to use than MANTA.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative proteinuria is associated with higher mortality after fenestrated/branched aortic repair of complex anatomy aortic aneurysms.","authors":"Vivian Carla Gomes, F Ezequiel Parodi, Priya Vasan, William A Marston, Luigi Pascarella, Katharine L McGinigle, Jacob C Wood, Ehsan Benrashid, Mark A Farber","doi":"10.1016/j.jvs.2025.05.039","DOIUrl":"10.1016/j.jvs.2025.05.039","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;Previous literature demonstrated an association between preoperative proteinuria and mortality after endovascular repair of juxtarenal aortic aneurysms. The aim of this study is to evaluate the association of preoperative proteinuria on 1- and 5-year survival after fenestrated/branched endovascular repair (F/BEVAR) of thoracoabdominal aortic aneurysms (TAAAs), pararenal aortic aneurysms, and juxtarenal aortic aneurysms treated with patient-specific company-manufactured devices (CMDs) or off-the-shelf devices. The impact on kidney function after F/BEVAR was also analyzed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was performed with prospectively collected data, including patients with complex anatomy aortic aneurysms who underwent F/BEVAR at a single institution from July 2012 to February 2024. All patients were treated with a company-manufactured device or off-the-shelf devices under a physician-sponsored investigational device exemption protocol. Patients were divided into two groups based on the preoperative urinalysis performed within 30 days before the index procedure: patients with trace or no proteinuria vs patients with proteinuria (1+, 30-100 mg/dL; 2+, 100-299 mg/dL; 3+, ≥300 mg/dL). Primary outcomes were 1-year and 5-year survival. Secondary outcomes were 30-day mortality, myocardial infarction, stroke/transient ischemic attack, acute kidney injury, and spinal cord ischemia. The follow-up protocol included imaging studies (chest, abdomen and pelvis computed tomography angiography, abdominal radiography, and renal-mesenteric duplex ultrasound examination) and laboratory analysis. Time-to-event analysis was performed with Kaplan-Meier plots compared through log-rank testing. Binary logistic regression model was designed to investigate predictors associated with 5-year survival after F/BEVAR.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 454 patients underwent the F/BEVAR procedure; patients were 71.5% male and 15.4% Black, with a mean age of 72 ± 5.2 years. Sixty-seven patients (14.7%) had preoperative proteinuria of ≥30 mg/dL. Patients with and without preoperative proteinuria were similar in terms of demographics, aneurysm extension, and comorbidities, except for chronic kidney disease and cerebrovascular disease, which were more prevalent in patients with proteinuria (P &lt; .001 and P = .011, respectively). There was no significant differences observed in 30-day mortality, acute kidney injury, spinal cord ischemia, stroke/transient ischemic attack, or myocardial infarction rates. The survival analysis demonstrated a significantly lower 1-year (77.9 ± 5.4% vs 89.4 ± 1.6%; P = .004) and 5-year survival (33.8 ± 8.8% vs 65.2 ± 3.0%; P = .002) among the patients with proteinuria when compared with individuals presenting trace or no proteinuria. Patients with preoperative proteinuria had a risk of death almost two times higher (odds ratio, 1.95; 95% confidence interval, 1.27-2.99; P = .002) and a ris","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative and long-term outcomes after Hemodialysis Reliable Outflow (HeRO) graft surgery.","authors":"Young Kim, Christina L Cui, Anthony Nnaemeka Eze, Tristen T Chun, Charles Y Kim, Ellen D Dillavou, Mitchell W Cox, Kevin W Southerland","doi":"10.1016/j.jvs.2025.05.042","DOIUrl":"10.1016/j.jvs.2025.05.042","url":null,"abstract":"<p><strong>Objective: </strong>The Hemodialysis Reliable Outflow (HeRO) graft offers hemodialysis access options for patients who have developed central venous stenosis or occlusion. In this single-center study, we report our perioperative and long-term outcomes after HeRO graft placement, and investigate the impact of conduit type and configuration on patency rates.</p><p><strong>Methods: </strong>We retrospectively reviewed all HeRO graft procedures performed from January 2014 to December 2023 across three hospitals. Data were collected on patient demographics, operative details, postoperative outcomes, and patency. Only index HeRO graft procedures were included, and any subsequent or reoperative HeRO operations were excluded from analysis. Cox proportional hazards model was used to derive risk factors for loss of graft patency.</p><p><strong>Results: </strong>A total of 232 index HeRO implantations were performed over the 10-year study period. These included 49 primary procedures (23.1%) and 183 staged procedures (78.9%). Postoperative complications included wound infection (n = 18; 7.8%), symptomatic hematoma (n = 23; 9.9%), steal syndrome (n = 23; 9.9%), myocardial infarction (n = 3; 1.3%), and pulmonary embolism (n = 7; 3.0%). Overall primary patency was 33.0% ± 3.4% at 1 year, 6.4% ± 2.1% at 3 years, and 4.3% ± 1.9% at 5 years post-implantation. Secondary patency was 69.4% ± 3.4% at 1 year, 41.9% ± 4.4% at 3 years, and 28.0% ± 4.9% at 5 years post-implantation. Primary and secondary patency rates did not differ between primary and staged procedures (log-rank P = .46 and .73, respectively). On multivariate analysis, the use of a tapered 4- to 6-mm (hazard ratio [HR], 2.89; 95% confidence interval [CI], 1.11-7.49; P = .029) or tapered 4- to 7-mm conduit (HR, 1.82; 95% CI, 1.15-2.87; P = .011) was independently associated with loss of primary patency, compared with a non-tapered 6-mm graft. Tapered conduits were also associated with loss of secondary patency (4- to 6-mm tapered: HR, 3.68; 95% CI, 1.07-12.63; P = .039; 4- to 7-mm tapered: HR, 1.85; 95% CI, 1.01-3.37; P = .044). Neither graft type (standard vs early cannulation) nor procedure (primary vs staged) were associated with loss of primary or secondary patency.</p><p><strong>Conclusions: </strong>Among patients with limited hemodialysis access options, HeRO graft implantation is associated with limited primary patency but acceptable secondary graft patency rates. In our experience, staged procedures and early cannulation grafts did not impact patency rates; however, the use of a tapered conduit was associated with loss of patency and should be considered with caution in this patient population.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of thoracic endovascular aortic repair for descending thoracic aortic aneurysms based on pooled results from FDA clinical trials.","authors":"Lauren A Gillinov, Grace J Wang, Nicholas J Goel, Michael A Catalano, Wilson Y Szeto, Venkat R Kalapatapu, Nimesh D Desai","doi":"10.1016/j.jvs.2025.05.038","DOIUrl":"10.1016/j.jvs.2025.05.038","url":null,"abstract":"<p><strong>Objective: </strong>Thoracic endovascular aortic repair (TEVAR) is the preferred treatment for descending thoracic aortic aneurysms, but long-term data are limited. This study assessed long-term results of TEVAR in early recipients of TEVAR devices who were enrolled in US Food and Drug Administration investigational device exemption clinical trials for aneurysm.</p><p><strong>Methods: </strong>This was a single-center retrospective study including 179 patients enrolled in 14 clinical trials for TEVAR for descending thoracic aortic aneurysm between 2000 and 2019. The primary outcome was 10-year mortality. Secondary outcomes included a 30-day composite of death or a neurologic event, endoleak, reintervention, and aortic diameter on follow-up imaging. Descriptive statistics, Kaplan-Meier survival analysis, Cox proportional hazards models, and cumulative incidence functions with competing risk were used for analysis.</p><p><strong>Results: </strong>The median patient age was 74 years and median follow-up was 5.5 years. Aneurysm morphology was fusiform (n = 100 [55.9%]) or saccular (n = 70 [39.1%]), with median preoperative diameter of 60.0 mm. Survival at 1, 5, and 10 years was 91.1%, 62.8%, and 31.4%. Endoleak was observed in 58 patients (32.4%), and reintervention in 44 patients (24.6%). Neither endoleak nor reintervention was associated with all-cause mortality at 10 years. Increasing age and preoperative aneurysm diameter were independent predictors of mortality. A majority of patients (73.8%) had stable aneurysm sac at 5 years.</p><p><strong>Conclusions: </strong>Although overall survival at 10 years was limited, early outcomes were favorable and most patients had stable aneurysm sac at 5 years. Endoleak and reintervention were not linked to long-term mortality, whereas age and preoperative aortic diameter predicted worse survival. In this older patient cohort, the durability of TEVAR remains a concern.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reintervention With In Situ Fenestration After Failure to Bridge Right Renal Artery During Endovascular Aortic Repair","authors":"Aslyn E. Mattson ,&nbsp;W. Anthony Lee","doi":"10.1016/j.jvs.2025.03.083","DOIUrl":"10.1016/j.jvs.2025.03.083","url":null,"abstract":"","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":"81 6","pages":"Page e25"},"PeriodicalIF":3.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Predictors of Prolonged Length of Stay Following Elective Aortobifemoral Bypass for Aortoiliac Occlusive Disease","authors":"Sina Zarrintan ,&nbsp;Pooria Nakhaei ,&nbsp;Elsie Ross MD ,&nbsp;Mahmoud Malas","doi":"10.1016/j.jvs.2025.03.085","DOIUrl":"10.1016/j.jvs.2025.03.085","url":null,"abstract":"","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":"81 6","pages":"Page e26"},"PeriodicalIF":3.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pursuit of a textbook outcome","authors":"Douglas W. Jones MD, MS","doi":"10.1016/j.jvs.2025.01.221","DOIUrl":"10.1016/j.jvs.2025.01.221","url":null,"abstract":"","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":"81 6","pages":"Page 1380"},"PeriodicalIF":3.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}